Project Grant R03AI185405
Award Date 7/2/24
Completion Date 5/31/26
Dollars Obligated $417K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Fort Collins, CO 80521, USA
Similar Awards
- Federal Grant Award Summary Award: Therapeutic Potential of Mycobacteriophage LYSB Against Mycobacterium Abscessus Infections The National Institute of Allergy and Infectious Diseases (NIAID) awarded Health Research, Inc.'s Wadsworth Center Division a $1.38 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 18, 2025, with completion targeted for June 30, 2030. This research initiative aims to develop D29 mycobacteriophage lysin (LYSB) as a...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a $486,470 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 11, 2025 through July 31, 2027. The award funds the development and validation of direct-from-sample whole genome sequencing (WGS) methods for Neisseria gonorrhoeae (NG) that eliminate the need for isolate culturing. These methodological advances will be applied to generate...
- Project Grant Summary Brigham and Women's Hospital received a $198,630 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2030. This award supports the development and validation of BADLOCK, a CRISPR-based diagnostic assay designed to rapidly identify bacterial species and antimicrobial resistance (AMR) genes from blood cultures in...
- L2 Diagnostics LLC received a $293,142 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 21, 2025, with a completion date of August 31, 2027. The award supports development of a rapid diagnostic test (RDT) in lateral flow assay (LFA) format for detecting Babesia microti infection. The test targets BMGPI12 (BMSA1), a secreted protein released into the...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
- Federal Grant Award Summary SKM Instruments, LLC received a $797,550 Project Grant from the Centers for Disease Control and Prevention (CDC) under the Prevention of Disease, Disability, and Death by Infectious Diseases program (CFDA 93.084) to develop an ultra-rapid optical platform for antimicrobial susceptibility testing (AST) of pulmonary non-tuberculous mycobacterial (NTM) infections. The award, effective September 30, 2025, with a completion date of May 31, 2026, supports research and...
- Federal Project Grant Award Summary Tufts Medical Center Parent, Inc. (Tufts Medical Center) received a $190,768 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 2, 2025, through August 31, 2028. The award funds development of a rapid transcriptomic assay for antimicrobial susceptibility testing (AST) of Mycobacterium abscessus, a nontuberculous mycobacterium...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Health Research, Inc.'s Wadsworth Center Division a $403,756 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 14, 2026, for completion by March 31, 2028. This research initiative focuses on mapping the determinants of bedaquiline (BDQ) resistance in Mycobacterium tuberculosis (MTB), an extensively drug-resistant pathogen. The project delivers a...
- Federal Cooperative Agreement Summary Seek Laboratories, Inc. received a $2.0 million Cooperative Agreement from the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) under the Plant and Animal Disease, Pest Control, and Animal Care program (CFDA 10.025), awarded February 2, 2026, with completion targeted for December 31, 2028. The award supports the development of a programmable CRISPR gene-editing platform designed to combat highly pathogenic avian influenza...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $473,937 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, for a project period extending through June 30, 2027. The award supports development of a novel point-of-care liquid biopsy diagnostic tool for early detection of sepsis-associated organ damage. The project leverages the institution's pioneering liquid biopsy...